Novel PSMA-targeted therapy highly active in mCRPC - Urology Times

Over 90% of patients had a ≥50% reduction in their PSA level when receiving the PSMA-targeted therapy 225Ac-PSMA-617.

Over 90% of patients with metastatic castration-resistant prostate cancer (mCRPC) who received the PSMA-targeted therapy 225Ac-PSMA-617 had a 50% or greater reduction in their PSA level, according to… [+3208 chars]

full article...